MX2018015873A - Preparacion de derivados del factor xa. - Google Patents

Preparacion de derivados del factor xa.

Info

Publication number
MX2018015873A
MX2018015873A MX2018015873A MX2018015873A MX2018015873A MX 2018015873 A MX2018015873 A MX 2018015873A MX 2018015873 A MX2018015873 A MX 2018015873A MX 2018015873 A MX2018015873 A MX 2018015873A MX 2018015873 A MX2018015873 A MX 2018015873A
Authority
MX
Mexico
Prior art keywords
protein
derivatives
factor
preparation
chromatograph
Prior art date
Application number
MX2018015873A
Other languages
English (en)
Inventor
Karbarz Mark
B Conley Pamela
Genmin Lu
Original Assignee
Portola Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60663351&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2018015873(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Portola Pharm Inc filed Critical Portola Pharm Inc
Publication of MX2018015873A publication Critical patent/MX2018015873A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6432—Coagulation factor Xa (3.4.21.6)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/20—Partition-, reverse-phase or hydrophobic interaction chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente descripción proporciona métodos para fabricar una proteína derivada de fXa a gran escala, lo que produce un alto rendimiento de producto proteico altamente puro. El método puede incluir agregar un detergente a una muestra que contiene una construcción de polinucleótidos que codifica la proteína y purifica la proteína a través de un cromatógrafo por afinidad basado en el inhibidor la tripsina de soja (STI), un cromatógrafo de modo mixto y de intercambio de iones y una interacción hidrofóbica.
MX2018015873A 2016-06-17 2017-06-19 Preparacion de derivados del factor xa. MX2018015873A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662351841P 2016-06-17 2016-06-17
PCT/US2017/038169 WO2017219034A2 (en) 2016-06-17 2017-06-19 Preparation of factor xa derivatives

Publications (1)

Publication Number Publication Date
MX2018015873A true MX2018015873A (es) 2019-08-12

Family

ID=60663351

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018015873A MX2018015873A (es) 2016-06-17 2017-06-19 Preparacion de derivados del factor xa.

Country Status (23)

Country Link
US (4) US10604748B2 (es)
EP (2) EP3926044A1 (es)
JP (3) JP6959268B2 (es)
KR (1) KR102373215B1 (es)
CN (3) CN118271391A (es)
AU (2) AU2017283720C1 (es)
BR (1) BR112018075964A2 (es)
CA (1) CA3027457A1 (es)
CL (2) CL2018003654A1 (es)
CO (1) CO2019000120A2 (es)
DK (1) DK3472314T3 (es)
EA (1) EA037815B1 (es)
ES (1) ES2875538T3 (es)
HU (1) HUE054597T2 (es)
IL (1) IL263591B2 (es)
MX (1) MX2018015873A (es)
PE (1) PE20190661A1 (es)
PH (1) PH12018502614A1 (es)
PL (1) PL3472314T3 (es)
PT (1) PT3472314T (es)
SG (1) SG11201810915QA (es)
SI (1) SI3472314T1 (es)
WO (1) WO2017219034A2 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2607935T3 (es) * 2009-03-30 2017-04-04 Portola Pharmaceuticals, Inc. Antídotos para inhibidores del factor Xa y procedimientos de uso de los mismos
CA2898975C (en) * 2013-01-24 2021-06-15 Portola Pharmaceuticals, Inc. Inhibition of tissue factor pathway inhibitor with factor xa derivatives
CN118271391A (zh) * 2016-06-17 2024-07-02 阿雷克森制药公司 因子xa衍生物的制备
WO2019246094A1 (en) * 2018-06-19 2019-12-26 Portola Pharmaceuticals, Inc. Antidotes to factor xa inhibitors
KR102337683B1 (ko) * 2018-09-21 2021-12-13 주식회사 녹십자 고효율 항-tfpi 항체 조성물

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5189019A (en) 1990-04-23 1993-02-23 Merck & Co., Inc. Antistasin derived anticoagulant protein
US5589571A (en) 1994-10-28 1996-12-31 Cor Therapeutics, Inc. Process for production of inhibited forms of activated blood factors
JPH1066572A (ja) * 1996-08-29 1998-03-10 Showa Sangyo Co Ltd 高純度の大豆トリプシンインヒビターの製造方法
EP1259485B1 (en) 2000-02-29 2005-11-30 Millennium Pharmaceuticals, Inc. BENZAMIDES AND RELATED INHIBITORS OF FACTOR Xa
BRPI0618362A2 (pt) 2005-11-08 2011-08-30 Millennium Pharm Inc sais farmacêuticos inovadores e polimorfos de um inibidor de fator xa
BRPI0816837B1 (pt) 2007-09-28 2022-10-18 Portola Pharmaceuticals, Inc Composições farmacêuticas, polipeptídeo isolado de duas cadeias e uso de uma composição farmacêutica
WO2010056765A2 (en) 2008-11-14 2010-05-20 Portola Pharmaceuticals, Inc. Antidotes for factor xa inhibitors and methods of using the same in combination with blood coagulating agents
ES2607935T3 (es) 2009-03-30 2017-04-04 Portola Pharmaceuticals, Inc. Antídotos para inhibidores del factor Xa y procedimientos de uso de los mismos
CA2767858C (en) 2009-07-15 2019-02-12 Portola Pharmaceuticals, Inc. Unit dose formulation of antidotes for factor xa inhibitors and methods of using the same
CA2876361C (en) * 2012-06-14 2020-06-30 Portola Pharmaceuticals, Inc. Method for purification of recombinant factor xa derivatives
US20140346397A1 (en) * 2012-12-27 2014-11-27 Portola Pharmaceuticals, Inc. Compounds and methods for purification of serine proteases
CA2898975C (en) 2013-01-24 2021-06-15 Portola Pharmaceuticals, Inc. Inhibition of tissue factor pathway inhibitor with factor xa derivatives
CN105579468A (zh) * 2013-09-24 2016-05-11 辉瑞大药厂 包含重组人凝血因子Xa蛋白的异质性群体的组合物
EA202091385A3 (ru) * 2014-08-20 2021-06-30 Портола Фармасьютикалз, Инк. Лиофилизированные составы для антидота фактора ха
CN118271391A (zh) * 2016-06-17 2024-07-02 阿雷克森制药公司 因子xa衍生物的制备

Also Published As

Publication number Publication date
HUE054597T2 (hu) 2021-09-28
JP2019528242A (ja) 2019-10-10
JP7273918B2 (ja) 2023-05-15
CN110167575A (zh) 2019-08-23
CN110167575B (zh) 2024-03-15
PT3472314T (pt) 2021-06-18
JP2023086970A (ja) 2023-06-22
ES2875538T3 (es) 2021-11-10
EP3926044A1 (en) 2021-12-22
AU2023200825A1 (en) 2023-03-16
US20200208131A1 (en) 2020-07-02
JP6959268B2 (ja) 2021-11-02
JP2022000477A (ja) 2022-01-04
IL263591B2 (en) 2023-03-01
DK3472314T3 (da) 2021-07-26
EA037815B1 (ru) 2021-05-25
WO2017219034A2 (en) 2017-12-21
IL263591A (en) 2019-02-03
CN116425860A (zh) 2023-07-14
KR102373215B1 (ko) 2022-03-10
AU2017283720A1 (en) 2019-01-03
AU2017283720B2 (en) 2022-11-17
EA201990052A1 (ru) 2019-05-31
CL2020001733A1 (es) 2020-09-25
CL2018003654A1 (es) 2019-01-25
PL3472314T3 (pl) 2021-11-22
PH12018502614A1 (en) 2019-09-30
IL263591B (en) 2022-11-01
US11845966B2 (en) 2023-12-19
SG11201810915QA (en) 2019-01-30
EP3472314A2 (en) 2019-04-24
SI3472314T1 (sl) 2021-11-30
EP3472314B1 (en) 2021-05-05
CN118271391A (zh) 2024-07-02
US10954504B2 (en) 2021-03-23
US20240076642A1 (en) 2024-03-07
WO2017219034A3 (en) 2019-03-14
US20170369862A1 (en) 2017-12-28
PE20190661A1 (es) 2019-05-08
CO2019000120A2 (es) 2019-03-29
US20210348149A1 (en) 2021-11-11
CA3027457A1 (en) 2017-12-21
EP3472314A4 (en) 2020-01-22
KR20190019134A (ko) 2019-02-26
AU2017283720C1 (en) 2024-07-25
BR112018075964A2 (pt) 2019-04-02
US10604748B2 (en) 2020-03-31

Similar Documents

Publication Publication Date Title
PH12018502614A1 (en) Preparation of factor xa derivatives
EP3708660A3 (en) Polypeptides
PH12018500707A1 (en) Anti-human cd19 antibodies with high affinity
IN2013MU02145A (es)
MX2018012016A (es) Compuestos biciclicos.
MX2018012085A (es) Compuestos agonistas de gpr119 y metodo para tratar enfermedades y afecciones mediado a traves de gpr119.
WO2018162557A3 (en) Method for purifying proteins using silicate
NZ711192A (en) Process for making benzoxazepin compounds
MX2018004300A (es) Uso de nuevas mezclas de isomero de (e/z) ciclopentadecenona, produccion y su uso como sustancia aromatizante.
MX360855B (es) Procedimiento para la preparación de una composición que comprende complejos metálicos en una matriz orgánica aceitosa.
MX2018004299A (es) Metodo para la purificacion de ciclohexadec-8-en-1-ona.
MX2016013416A (es) Nuevo proceso de purificacion de gonadotropina.
MX2019015499A (es) Método para producir d-psicosa a partir de un complejo de borato y d-psicosa usando cromatografía y composición que contiene d-psicosa.
BR112017025872A2 (pt) proteínas de ligação multiespecíficas
MX2017005988A (es) Compuestos intermediarios para la produccion de ingredientes perfumantes.
MX2019004182A (es) Proceso para la fabricacion de 2,6-dimetil-5-hepten-1-al.
GB2514940A (en) Process and method for the treatment of materials, materials thus obtained and uses of these materials
EP3129342A4 (en) Process for the isolation of 1,2,5,6-hexanetetrol from sorbitol hydrogenolysis reaction mixtures using simulated moving bed chromotography
MX366198B (es) Método para separar y purificar lactoferrina humana recombinada a partir de semillas de arroz.
JO3712B1 (ar) طريقة لتحضير 1-(4-ميثان سلفونيل-2-تراي فلورو ميثيل-بنزيل)-2ميثيل-1h-بيرولو[2، 3-b]بيريدين-3-يل-حمض أسيتيك
EA202190557A1 (ru) СПОСОБЫ ПОЛУЧЕНИЯ 4-{8-АМИНО-3-[(2S)-1-(БУТ-2-ИНОЛ)ПИРРОЛИДИН-2-ИЛ]ИМИДАЗО[1,5-a]ПИРАЗИН-1-ИЛ}-N-(ПИРИДИН-2-ИЛ)БЕНЗАМИДА
PH12014501220A1 (en) Removal of components from a starting material
NZ742210A (en) Neospora vaccine composition
MX2016011534A (es) Un proceso mejorado para la preparacion de exametazima.
PH12017500291A1 (en) Purification of polyphenols